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We examined the relation between coffee drinking and hepatocellular carcinoma (HCC) mortality in the Japan Collaborative Cohort
Study for Evaluation of Cancer Risk (JACC Study). In total, 110688 cohort members (46399 male and 64289 female subjects) aged
40–79 years were grouped by coffee intake into three categories: one or more cups per day, less than one cup per day and non-
coffee drinkers. Cox proportional hazards model by SAS was used to obtain hazard ratio of HCC mortality for each coffee
consumption categories. The hazard ratios were adjusted for age, gender, educational status, history of diabetes and liver diseases,
smoking habits and alcohol. The hazard ratio of death due to HCC for drinkers of one and more cups of coffee per day, compared
with non-coffee drinkers, was 0.50 (95% confidence interval 0.31–0.79), and the ratio for drinkers of less than one cup per day was
0.83 (95% confidence interval 0.54–1.25). Our data confirmed an inverse association between coffee consumption and HCC
mortality.
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Hepatocellular carcinoma (HCC) has a high incidence in
Africa and Asia where Hepatitis B virus (HBV) or Hepatitis C
virus (HCV) infection are major risk factors (Tabor, 1998).
Heavy alcohol consumption (La Vecchia et al, 1988; Tanaka
et al, 1992) and dietary aflatoxins (Bulatao-Jayme et al, 1982;
Yu et al, 1999) increase the risk of HCC, while diabetes (La Vecchia
et al, 1997), smoking (La Vecchia et al, 1988; Yu et al, 1999) and
low education level (La Vecchia et al, 1988) are also reported risk
factors.
Coffee drinking has been inversely related to the risk
of liver cirrhosis in several studies (Klatsky and Armstrong,
1992; Klatsky et al, 1993; Corrao et al, 1994, 2001; La Vecchia
et al, 1998; Gallus et al, 2002a), although no significant relation
was found in two case–control studies from Italy (La Vecchia
et al, 1989) and Greek (Kuper et al, 2000). To investigate further
an association between coffee drinking and HCC mortality,
we analysed data from the Japan Collaborative Cohort Study
for Evaluation of Cancer Risk sponsored by Monbusho (JACC
Study).
SUBJECT AND METHODS
Subjects
Subjects were 110792 cohort members (46465 males and 64327
females) aged 40–79 years from JACC Study, the design of which
has been previously described (Ohno et al, 2001). The subjects
were followed up from 1988–1990 until the end of 1999.
Residential and survival status was confirmed by searching in
roster of residents for moving out or death, and in death certificate
for cause and date of death under the permission from the
Director-General of Prime Minister’s Office.
End point for the present study was death from HCC, coded
as C22.0 in International Classification of Diseases and Related
Health Problems, 10th Revision (ICD-10). Subjects with HCC at
baseline or died from HCC within 2 years after registration in
the study were excluded from the analysis. Subjects coded C22.9
(hepatic malignancy not otherwise specified) were also excluded
from the analysis. The total number of subjects was 110688 (46399
males and 64289 females). The subjects who died of HCC during
the observation periods were 287 male and 114 female subjects.
Questionnaire and data correction
After obtaining the informed consent to participate the study,
subjects were interviewed or completed questionnaire. A self-
administered questionnaires for the survey included past and
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smoking, alcohol and non-alcohol beverages, diet, physical
exercise, occupation and others. On the questionnaire, habitual
coffee consumption was queried by the question’ Do you drink
coffee? ‘The response sets was: ‘almost everyday’; ‘3–4 cups per
week’; ‘1–2 cups per week’; ‘1–2cups per month’; ‘scarcely any’.
Those who answered ‘almost everyday’ were asked to report the
number of cups of coffee per day. Study participants were grouped
into three groups as follows: one or more cups per day, less than
one cup per day and 0 cup per day (non coffee drinkers). Drinkers
of less than one cup per day included those of ‘3–4 cups per week’,
‘1–2 cups per week’ and ‘1–2cups per month’.
Each data set was transformed into the format of the JACC Study
standard questionnaire, submitted to central office. Integrated data
were tested in distribution and logical accuracy by working group
for data clean up. More detailed process was described elsewhere
(Shibata et al, 2003).
Data analysis
SAS version 8.2. software (SAS institute, Cary, NC, USA) was used
for the statistical analysis. To examine the association between
the potential confounding factors and coffee consumption, we
calculated the age-adjusted proportions and mean values for each
factor at each coffee level. Cox proportional hazards model by SAS
PHREG with strata statement (difference of collaborating institutes)
was used to obtain hazard ratio (HR) of HCC mortality for each
coffee consumption categories. Multiple logistic regression analysis
was used to analyse the trends in adjusted means and proportion.
P-values for trends in the Cox analysis were calculated by assigning
a median value of cups per day to each categories. Chi-squared test
was used to assess differences between proportions. All results were
considered to be significant at the 5% critical level.
This study was approved by the Ethics Committee of the
Kurume University School of Medicine.
RESULTS
Table 1 shows the age distribution and the age-adjusted rates of
lifestyle characteristics by coffee consumption categories. Persons
who consumed larger amount of coffee tended to be younger.
Coffee consumption was associated with education level, smoking
and alcohol habits.
Table 2 shows HRs of death from HCC according to coffee
consumption. The HR of death due to HCC for drinkers of one and
more cups of coffee per day, compared with non-coffee drinkers,
was 0.50 (95% confidence interval 0.31–0.79), and the ratio for
drinkers of less than one cup per day was 0.83 (95% confidence
interval 0.54–1.25). The HR of death due to HCC was significantly
decreased among drinkers of one or more cups of coffee per day
compared with non-coffee drinkers in men, but not in women.
When the analysis was restricted to subjects with a history of liver
disease, the HR of death due to HCC significantly decreased for
drinkers of one and more cups of coffee per day compared with
non-coffee drinkers. The decrease in risk was not significant when
the analysis was restricted to subjects who did not report history of
liver diseases.
DISCUSSION
No consistent association emerged between coffee consumption
and the risk of HCC. Recently, Gallus et al (2002b) reanalysed the
Italian (La Vecchia et al, 1989, 1998) and Greek (Kuper et al, 2000)
case–control studies of HCC and found an inverse association
between coffee drinking and HCC risk. Japanese workers (Inoue
et al, 2005) reported from 10-year follow-up data of the Japan
Public Health Center-based Prospective (JPHC) Study that habitual
coffee drinking may be associated with reduced risk of HCC.
Further studies are warranted to determine whether the inhibitory
effect applies to other population. We performed multivariate
analysis of an association between coffee drinking and HCC
mortality controlling the potential confounding factors age,
gender, history of liver diseases, alcohol, smoking, education
level, and diabetes in the JACC study. Our data showed an inverse
association between coffee consumption and HCC mortality. Thus,
the inhibitory effect of coffee drinking has been observed in the
two different large-scale cohort studies.
In Japan, approximately 80% of HCC cases are associated with
HCV (Yoshizawa, 2002). The multivariate HR of HCC mortality
among coffee drinkers significantly decreased among those with a
Table 1 Potential confounding factors acccording to coffee consumption categories by gender
Men Women
Non-drinkers oa cup day
1 Xa cup day
1 Trend P Non-drinkers oa cup day
1 Xa cup day
1 Trend P
No 12461 9490 21828 19346 12710 28767
Age (%)
40–49 years 16.0 23.3 32.1 13.8 24.7 31.1
50–59 years 30.6 31.4 29.5 31.3 33.8 29.9
60–69 years 36.0 31.0 26.0 36.8 29.4 26.9
70–79 years 17.4 14.3 12.4 18.1 12.1 12.1
Education
a(%) 11.0 12.1 23.7 o0.001 7.4 8.1 14.3 o0.001
Smoking habits
Currently smokes(%) 45.2 48.7 55.9 o0.001 3.7 4.0 7.3 o0.001
Smoked in the past(%) 30.5 29.4 25.7 0.295 1.7 2.0 2.0 0.354
Alcohol habits
Currently drinks (%) 78.3 75.5 72.1 o0.001 17.9 26.4 26.5 o0.001
Drank in the past (%) 8.3 6.5 6.3 0.099 1.8 1.6 1.8 0.457
Liver disease (%) 9.9 8.9 7.4 0.845 6.6 6.8 5.3 0.109
Diabetes mellitus (%) 9.0 7.7 6.5 0.251 6 4.1 4.2 0.492
aEducation: age at final graduation of 18 years old or more.
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a history. The effect of coffee drinking on hepatocellular cartino-
genesis may be associated with inhibiting the progression from
hepatitis to cirrhosis or from cirrhosis to HCC. Another possible
explanation is that persons might reduce coffee intake because
of symptoms related to impaired caffeine clearance (Hasegawa
et al, 1989) of poor liver function or nonspecific medical advice.
Coffee consumption, however, was not significantly associated
with history of liver diseases at baseline survey. Animal data have
suggested an inhibitory effect of coffee on HCC (Tanaka et al,
1990). The inhibitory effect of coffee may be related to inhibition
on the process of nitrosamine formation or hepatocarcinogenesis
by nitrosamines. As for a possible effect of caffeine, green tea
which contains caffeine is not significantly associated with HCC
mortality in univariate analysis of the JACC Study (Kurozawa et al,
2004). The absence of serum markers for HCV or HBV infection is
a major limitation, although HRs were adjusted by history of liver
disease. Although the mechanism of the inhibitory effect is not
clear, coffee drinking may have a real effect in reducing HCC
mortality.
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